文献速递哮喘

ERS SHARP重度哮喘登记库患者特征与治疗方案差异

Characteristics and treatment regimens across ERS SHARP severe asthma registries.
PubMed 文献 · Eur Respir J · 2020-01-09

该研究基于11个欧洲国家重度哮喘登记库的3236例患者数据,比较开始生物制剂治疗前的患者特征与治疗方案。结果显示各国在吸烟率、体重指数、肺功能及吸入/口服激素使用上差异显著,部分患者特征不符合ERS/ATS重度哮喘指南定义,且治疗与临床试验入组标准不一致。

要点

  • 欧洲重度哮喘患者临床特征与治疗高度异质,各国差异明显。
  • 开始生物制剂前吸入激素剂量与口服激素使用比例因国家而异。
  • 部分患者不符合ERS/ATS重度哮喘指南定义,治疗与试验标准脱节。

核心结论

  • 欧洲重度哮喘人群高度异质,临床特征与治疗差异大,部分不符合ERS/ATS指南定义。
  • 开始生物制剂前的治疗方案与临床试验入组标准不同,且各国间存在差异。

研究设计与样本

  • 横断面回顾性分析,汇总11个加入SHARP的国家重度哮喘登记库数据,共3236例患者。

主要发现

  • 当前吸烟率从0%(波兰、瑞典)到9.5%(比利时),平均BMI从26.2(意大利)到30.6 kg·m-2(英国)。
  • 支气管舒张前FEV1占预计值百分比均值最大差异为20.9%(荷兰与匈牙利之间)。
  • 开始抗IL-5治疗者吸入激素日均剂量在斯洛文尼亚与波兰间为700至1335 µg·day-1,抗IgE治疗者在斯洛文尼亚与西班牙间为772至1344 µg·day-1。
  • 维持口服激素使用率在抗IL-5治疗者中从21.0%(比利时)到63.0%(瑞典),抗IgE治疗者中从9.1%(丹麦)到56.1%(英国)。

临床怎么用

  • 临床应关注欧洲重度哮喘患者特征与治疗的异质性,评估是否符合ERS/ATS指南定义。
  • 开始生物制剂前需审视既往治疗方案与临床试验标准的差距,个体化决策。

局限性

  • 横断面回顾性分析,仅汇总登记库数据,可能存在选择偏倚与信息偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Little is known about the characteristics and treatments of patients with severe asthma across Europe, but both are likely to vary. This is the first study in the European Respiratory Society Severe Heterogeneous Asthma Research collaboration, Patient-centred (SHARP) Clinical Research Collaboration and it is designed to explore these variations. Therefore, we aimed to compare characteristics of patients in European severe asthma registries and treatments before starting biologicals.This was a cross-sectional retrospective analysis of aggregated data from 11 national severe asthma registries that joined SHARP with established patient databases.Analysis of data from 3236 patients showed many differences in characteristics and lifestyle factors. Current smokers ranged from 0% (Poland and Sweden) to 9.5% (Belgium), mean body mass index ranged from 26.2 (Italy) to 30.6 kg·m-2 (the UK) and the largest difference in mean pre-bronchodilator forced expiratory volume in 1 s % predicted was 20.9% (the Netherlands versus Hungary). Before starting biologicals patients were treated differently between countries: mean inhaled corticosteroid dose ranged from 700 to 1335 µg·day-1 between those from Slovenia versus Poland when starting anti-interleukin (IL)-5 antibody and from 772 to 1344 µg·day-1 in those starting anti-IgE (Slovenia versus Spain). Maintenance oral corticosteroid use ranged from 21.0% (Belgium) to 63.0% (Sweden) and from 9.1% (Denmark) to 56.1% (the UK) in patients starting anti-IL-5 and anti-IgE, respectively.The severe asthmatic population in Europe is heterogeneous and differs in both clinical characteristics and treatment, often appearing not to comply with the current European Respiratory Society/American Thoracic Society guidelines definition of severe asthma. Treatment regimens before starting biologicals were different from inclusion criteria in clinical trials and varied between countries.

来源:Eur Respir J,查看原文。版权归原作者所有。

引用

  1. van Bragt JJMH, Adcock IM, Bel EHD, et al. Characteristics and treatment regimens across ERS SHARP severe asthma registries. Eur Respir J. 2020. PMID: 31601713. doi:10.1183/13993003.01163-2019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。